Education
About Us
Working with TipRanks
Follow Us
Arbutus Biopharma (ABUS)
:ABUS
Total Valuation
Arbutus Biopharma has a market cap or net worth of $628.06M. The enterprise value is $504.68M.
Market Cap$628.06M
Enterprise Value$504.68M
Share Statistics
Arbutus Biopharma has 191.48M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding191.48M
Owned by Insiders1.18%
Owned by Instutions<0.01%
Financial Efficiency
Arbutus Biopharma’s return on equity (ROE) is -0.72 and return on invested capital (ROIC) is -65.47%.
Return on Equity (ROE)-71.81%
Return on Assets (ROA)-53.09%
Return on Invested Capital (ROIC)-65.47%
Return on Capital Employed (ROCE)-65.74%
Revenue Per Employee$140,250
Profits Per Employee-$1,589,090.909
Employee Count44
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arbutus Biopharma is -8.68. Arbutus Biopharma’s PEG ratio is 0.64.
PE Ratio-8.68
PS Ratio98.35
PB Ratio6.23
Price to Fair Value6.23
Price to FCF-9.36
Price to Operating Cash Flow-9.36
PEG Ratio0.64
Income Statement
In the last 12 months, Arbutus Biopharma had revenue of $6.17M and earned -$69.92M in profits. Earnings per share was -$0.31.
Revenue$6.17M
Gross Profit$5.46M
Operating Income-$75.93M
Pretax Income-$69.92M
Net Income-$69.92M
EBITDA-68.40M
Earnings Per Share (EPS)-0.31
Cash Flow
In the last 12 months, operating cash flow was -$64.61M and capital expenditures -$181.00K, giving a free cash flow of -$50.53M billion.
Operating Cash Flow-$64.61M
Free Cash Flow-$50.53M
Free Cash Flow per Share-$0.26
Dividends & Yields
Arbutus Biopharma pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield-10.68%
Earnings Yield-11.52%
Stock Price Statistics
Beta0.23
52-Week Price Change8.22%
50-Day Moving Average3.32
200-Day Moving Average3.60
Relative Strength Index (RSI)45.88
Average Volume (3m)1.18M
Important Dates
Arbutus Biopharma upcoming earnings date is May 1, 2025, After Close.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 1, 2025
Ex-Dividend Date―
Financial Position
Arbutus Biopharma as a current ratio of 8.15, with Debt / Equity ratio of 0.01
Current Ratio8.15
Quick Ratio8.15
Debt to Market Cap<0.01
Net Debt to EBITDA0.51
Interest Coverage Ratio-557.07
Taxes
In the past 12 months, Arbutus Biopharma has paid -$2.00 in taxes.
Income Tax-$2.00
Effective Tax Rate0.00%
Enterprise Valuation
Arbutus Biopharma EV to EBITDA ratio is -8.36, with an EV/FCF ratio of -8.82.
EV to Sales92.68
EV to EBITDA-8.36
EV to Free Cash Flow-8.82
EV to Operating Cash Flow-8.82
Balance Sheet
Arbutus Biopharma has $122.62M in cash and marketable securities with $1.29M in debt, giving a net cash position of -$121.33M billion.
Cash & Marketable Securities$122.62M
Total Debt$1.29M
Net Cash-$121.33M
Net Cash Per Share-$0.63
Tangible Book Value Per Share$0.52
Margins
Gross margin is 100.00%, with operating margin of -1236.74%, and net profit margin of -1133.04%.
Gross Margin100.00%
Operating Margin-1236.74%
Pretax Margin-1133.04%
Net Profit Margin-1133.04%
EBITDA Margin-1108.46%
EBIT Margin-1130.82%
Analyst Forecast
The average price target for Arbutus Biopharma is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$5.00
Price Target Upside58.23%
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-65.98%
EPS Growth Forecast14.00%